Colorectal Cancer Therapeutics Market Worth $16.58 Billion by 2026; Serious Impacts of Colorectal Cancer on Human Health Leading to Metastasis of Cancer Will Propel Growth

The global colorectal cancer therapeutics market size will reach USD 16.58 billion by 2026, prophesizes a Fortune Business Insights™ report titled, “Colorectal Cancer Therapeutics Market Size, Share & Industry Analysis, By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Others), By Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026.”According to the report, the global colorectal cancer therapeutics market size will rise from USD 9.26 Billion in 2018 and exhibit a CAGR of 7.6 % during the forecast period, 2019 to 2026.

Rising Awareness About Presence of Novel Therapeutics to Drive Market

The rise in the prevalence of colorectal cancer is a major factor in boosting colorectal cancer drug market growth. In addition, the launch of a number of novel therapeutics for a cancer cure and the rise in awareness about the presence of effective therapeutics worldwide is further expected to help increase the overall colorectal cancer therapeutics market size in the forecast period.

In-depth Segmentation of Colorectal Cancer Therapeutics Market

Therapy – Based on therapy, the market is categorized into immunotherapy, targeted therapy, chemotherapy, and others. Among these, the targeted therapy segment has emerged dominant on account of critical life-preserving functions that are performed by this segment. Besides this, the presence of a large number of prominent targeted therapies such as Stivarga, Erbitux, and Avastin, are also expected to help this region continue dominating the market in the forecast period as well. On the other side, the immunotherapy segment with a colorectal cancer therapeutics market share of 24.1% is likely to witness steady growth in the forecast period.

Cancer Type – With respect to cancer type, the market is classified into gastrointestinal carcinoid tumors, colorectal adenocarcinoma, and others. Out of these, the market is likely to witness the fastest growth rate from the colorectal adenocarcinoma segment. This is attributable to the fact that colorectal adenocarcinoma is the most common cancer type of colorectal cancer and contributes to colorectal cancer’s status as the fourth leading cause of cancer-related deaths.

Distribution Channel – In terms of distribution channels, the market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, and others. Among these, the hospital pharmacies segment is expected to hold the dominant colorectal cancer medications market share. This is because a licensed practitioner only issues the appropriate therapeutics for colorectal cancer after a complete diagnosis conducted mostly at hospitals.

Region – Geographically, the market is widespread into Europe, North America, Asia Pacific, Latin America, and the Middle East and Africa. These regions are further categorized into countries. In 2018, North America generated a colorectal cancer drugs market revenue of USD 4.13 billion and emerged dominant. This is on account of the rise in the prevalence of colorectal cancer and the increasing number of product launches in the region.

Robust Pipeline Candidates and Key Strategic Decisions to Help Leading Companies Enjoy Dominance in Market

Currently, companies, namely Merck Sharp & Dohme Corp., Genentech, Inc., and Bristol Myers Squibb, are holding the dominant colorectal cancer therapeutics market share. This is owing to the strong oncology product portfolio, key strategic decisions, product launches, FDA approvals, and robust pipeline candidates.

To get a detailed report summary and research scope of this market, click here: https://www.fortunebusinessinsights.com/industry-reports/colorectal-cancer-therapeutics-market-101945

Recent key industry developments of colorectal cancer therapeutics market include:

July 2018 – The accelerated approval of ipilimumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMr) was granted by the Food and Drug Administration on July 10, 2018. This drug will be combined with nivolumab and utilized for treating colorectal cancer patients above the age of 12. Further studies are still required for confirming the clinical benefit of nivolumab and ipilimumab for the particular indication, as a condition of accelerated approval.

July 2019 – Amgen and Allergan launched the first biosimilars for anticancer, namely Mvasi and Kanjinti in the U.S. These biosimilars are launched for colorectal cancer medication.

Some of the key colorectal cancer drugs market manufacturers are as follows:

• Ipsen Biopharmaceuticals, Inc.


• Teva Pharmaceutical Industries Ltd.


• Regeneron Pharmaceuticals, Inc.


• Taiho Pharmaceutical (Otsuka Pharmaceutical Co., Ltd.)


• Merck Sharp & Dohme Corp.


• Eli Lilly and Company


• Bristol Myers Squibb


• Genentech, Inc.


• Novartis AG


• Sanofi


• Pfizer Inc.


• Bayer AG

The global colorectal cancer drugs market is categorized in the following manner: